Guardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024. In the quarter to June 2026, revenue grew 44.3%, EPS fell 12.5%, free cash flow fell 5.46% and total debt rose 34.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow GH
Guardant Health, Inc. (GH) EV/Sales
As of 16 October 2026, Guardant Health, Inc. (GH) trades at a EV/Sales of 18.2×. Over the past ten years it has ranged from 1.4× (October 2018) to 66.6× (June 2019); the current reading is higher than 59% of that period. That is above the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 13.3× | 143.42% |
| FY2024 | 5.5× | 5.18% |
| FY2023 | 5.2× | (18.76%) |
| FY2022 | 6.4× | (76.80%) |
| FY2021 | 27.7× | (31.50%) |
| FY2020 | 40.4× | 31.22% |
| FY2019 | 30.8× | 285.22% |
| FY2018 | 8.0× | 310.90% |
| FY2017 | 1.9× | 0.00% |
| FY2016 | 1.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 17.2× | 48.57% |
| Mar 2026 | 11.6× | (13.12%) |
| Dec 2025 | 13.3× | 44.59% |
| Sep 2025 | 9.2× | 10.17% |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICLR ICON PLC compare | 1.9× |
| LH Labcorp Holdings Inc. compare | 2.2× |
| DGX Quest Diagnostics Incorporated compare | 2.7× |
| CRL Charles River Laboratories International, Inc. compare | 4.2× |
| MEDP Medpace Holdings, Inc. compare | 6.1× |
| RVTY Revvity Inc. compare | 6.6× |
| MTD Mettler-Toledo International, Inc. compare | 8.4× |
| ILMN Illumina, Inc. compare | 9.0× |
| GH Guardant Health, Inc. | 18.2× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)